Nutritional composition for promoting absorption of amino acids and minerals and application

Abstract

The invention discloses a nutritional composition for promoting absorption of amino acid and mineral substances and application, and belongs to the technical field of food. The nutritional composition provided by the invention comprises alpha-lactalbumin, casein phosphopeptides (CPP) and / or 2 '-fucosyllactose (2'-FL), can effectively promote the absorption of an organism to amino acids and minerals, and especially can significantly improve the absorption efficiency by enhancing the transmembrane transport capability of intestinal cells to amino acids and minerals.

Description

TECHNICAL FIELD

[0001] The present application relates to a nutrient composition for promoting the absorption of amino acids and minerals and application, belonging to the field of food technology. BACKGROUND

[0002] Protein is the material basis for the early development of life, and is essential for the growth and development and physiological function of infants, and will affect growth, body composition, neural development, appetite and hormone regulation, etc. Protein digestion problems can lead to short-term and long-term adverse consequences, such as pain, diarrhea, intolerance, allergy, malabsorption and constipation. Protein is composed of amino acids, which are essential nutrients for infants. Amino acids are divided into essential and non-essential amino acids according to whether the human body can synthesize them. Essential amino acids include valine, isoleucine, leucine, phenylalanine, methionine, tryptophan, threonine, lysine and histidine, which are not synthesized by the human body or synthesized at a speed insufficient to meet the needs, and therefore must be obtained through food. The composition of amino acids in cow's milk protein is quite different from that of breast milk, making the protein quality of infant formula based on cow's milk as the main protein source relatively low, and the bioavailability of amino acids relatively low. Although the ratio of whey protein and casein in infant formula milk powder has been optimized, there are still differences in digestion and absorption characteristics compared with breast milk. Therefore, it is necessary to adjust and optimize the formula of infant formula during development to improve the quality of protein and improve the bioavailability of amino acids, and promote the absorption of amino acids by infants.

[0003] Mineral elements such as calcium, magnesium, zinc and iron play an important role in the development of infant bones, teeth, immune system and intelligence. The mineral elements in breast milk have higher absorption and utilization rate, so the current national standard recommends a higher level of mineral fortification in infant formula than the general level in breast milk. Therefore, how to improve the absorption rate of minerals has become a key problem that needs to be solved in current technical development. The absorption of minerals such as calcium, magnesium, zinc and iron is affected by many factors such as the age and health status of the body, other nutrients in the diet, eating habits, drugs, etc. Therefore, targeted adjustment and optimization of the composition of nutrients is one of the solutions to improve their digestion and absorption efficiency.

[0004] In the face of the differences between formula milk powder and breast milk, researchers are constantly developing new functional raw materials in order to make formula milk powder closer to breast milk in terms of nutritional composition and function.

[0005] Currently, some progress has been made in the study of amino acid absorption mechanisms. For example, reference 1 reports a kind of infant formula food capable of improving the bioavailability of stable amino acids and its application. The formula contains α-lactalbumin, linoleic acid and prebiotics, which can enhance the digestion and absorption of acid-stable amino acids and contribute to the healthy development of infants. Reference 2 introduces a strain of Lactobacillus plantarum with the function of promoting amino acid absorption, with the preservation number of CGMCC NO.25190. In addition, reference 3 discloses an amino acid absorption promoter, the main component of which is one or more combinations of matobianic acid and / or its salts.

[0006] In terms of improving mineral absorption, existing research has proposed various effective strategies. Reference 4 introduces a composition that can synergistically enhance the bioavailability of minerals, which includes lutein, casein phosphopeptide or 1,3-dioleic acid-2-palmitic acid glycerol triester, and is recommended to be used in combination with one or more indigestible oligosaccharides. The composition can be used to prevent and / or treat mineral deficiency and related diseases, especially for anemia, wherein the minerals mainly include iron and / or calcium. On the other hand, reference 5 discloses a Lactiplantibacillus plantarum strain with the preservation number of CGMCC No.32404, which has the function of promoting mineral absorption and transport.

[0007] Although existing research has revealed the different promoting effects of various optional additives in infant formula milk powder or functional food on nutrient absorption, the sufficiency of these researches still needs to be further improved. At present, the academic community has rich research on the nutrient absorption function of single component, but there is still a lack of clear understanding of whether the combination of multiple components can produce synergistic effect, especially in promoting the simultaneous digestion and absorption of multiple nutrients such as amino acids and minerals. Therefore, the present application aims to develop a nutritional composition through scientific combination of multiple components, in order to achieve more effective promotion of the common digestion and absorption of multiple essential nutrients by the body, thereby making up for the shortcomings of existing research and providing a scientific basis for the optimization of infant formula milk powder.

[0008] Reference:

[0009] Reference 1: CN118901799A;

[0010] Reference 2: CN116286462A;

[0011] Reference 3: JP2024122087A;

[0012] Reference 4: CN119836289A;

[0013] Reference document 5: CN120424829A. SUMMARY

[0014] Problem to be solved by the invention

[0015] Although previous studies have shown that various optional additives in infant formula can promote the absorption of nutrients in different ways, the adequacy of these studies still needs to be further improved. At present, the academic community has conducted extensive research on the nutritional absorption function of single ingredients, but there is still a lack of clear understanding of whether the combination of multiple ingredients can produce a synergistic effect, especially in promoting the simultaneous digestion and absorption of multiple nutrients such as amino acids and minerals. Therefore, the present application aims to achieve more effective promotion of the simultaneous digestion and absorption of multiple essential nutrients in the body by scientifically combining α-lactalbumin, CPP (casein phosphopeptide), and 2'-FL (2'-fucosyllactose), thereby making up for the shortcomings of existing research and providing a scientific basis for the optimization of infant formula.

[0016] Solution to the problem

[0017] [1]. The present application first provides a nutritional composition for promoting the absorption of amino acids and minerals, wherein the nutritional composition comprises the necessary active ingredients as shown in (i) and (ii) below:

[0018] (i) α-lactalbumin;

[0019] (ii) one or both of casein phosphopeptide and 2'-fucosyllactose;

[0020] wherein in the nutritional composition, the mass ratio of the necessary active ingredients as shown in (i) to the necessary active ingredients as shown in (ii) is (80-250):(3-90).

[0021] [2]. The nutritional composition according to [1], wherein the component (ii) comprises casein phosphopeptide and 2'-fucosyllactose;

[0022] and the mass ratio of the α-lactalbumin, the casein phosphopeptide, and the 2'-fucosyllactose is (80-250):(3-10):(40-80).

[0023] [3]. The nutritional composition according to [1] or [2], wherein the nutritional composition further comprises one or more of other types of whey protein other than α-lactalbumin, other types of bovine milk protein derivatives other than casein phosphopeptide, and other types of breast milk oligosaccharides other than 2'-fucosyllactose.

[0024] [4]. Use of the nutritional composition according to any one of [1] to [3] in the manufacture of a foodstuff for facilitating absorption of amino acids and minerals.

[0025] [5]. The use according to [4], wherein the amino acids comprise essential and / or non-essential amino acids.

[0026] [6]. The use according to [4] or [5], wherein the minerals comprise one or more of calcium, zinc, magnesium and iron.

[0027] [7]. The use according to any one of [4] to [6], wherein the facilitating absorption of amino acids and minerals comprises facilitating expression of an amino acid transporter gene and / or an oligopeptide transporter gene.

[0028] [8]. The use according to any one of [4] to [7], wherein the foodstuff is a confectionery, a beverage, a dairy product or a bakery product.

[0029] [9]. The use according to any one of [4] to [8], wherein the foodstuff is an oral formulation; the oral formulation comprises at least one form of a tablet, a pill, a granule, a powder, a capsule, a beverage, a jelly, a gummy and an oral liquid.

[0030] Effects of the invention

[0031] Disclosed herein are compositions comprising alpha-lactalbumin, and CPP and / or 2'-FL, which can facilitate absorption of amino acids and minerals by the body, in particular, the transmembrane transport capacity of intestinal cells to amino acids and minerals, thereby improving the absorption efficiency.

[0032] Specifically, the compositions can improve the transport ratio of free total amino acids, minerals (calcium, zinc, magnesium, iron), facilitate the expression of amino acid transporter (SLC6A14) gene, oligopeptide transporter (PEPT1) gene. And when the mass of alpha-lactalbumin, and CPP and / or 2'-FL is within a certain range, there is a synergistic effect between the two or three. DETAILED DESCRIPTION

[0033] Various exemplary embodiments, features, and aspects of the present application will be described in detail below. The word "exemplary" is used herein to mean "serving as an example, instance, or illustration." Any implementation described herein as "exemplary" is not necessarily to be construed as preferred or advantageous over other implementations.

[0034] In addition, for purposes of explanation, numerous specific details are set forth in the description below. It is to be understood that the application can be practiced without certain specific details. In some instances, well-known methods, structures, apparatuses, and techniques have not been shown in detail in order not to obscure the application.

[0035] Unless otherwise indicated, units used in the description herein are in accordance with international standard units, and the numerical values, numerical ranges, appearing in the present application should be understood to include system errors that are unavoidable in industrial production.

[0036] In the present specification, the meaning indicated by "may" includes both the meaning that a certain process is performed and the meaning that a certain process is not performed.

[0037] In the present specification, the expressions "some embodiments / pref erred embodiments", "other embodiments / pref erred embodiments", "embodiments", and the like mean that the particular feature (e.g., characteristic, structure, property, and / or characteristic) described is included in at least one embodiment described herein, and can exist in some embodiments or can not exist in other embodiments. In addition, it should be understood that the described features can be combined in any suitable manner in various embodiments.

[0038] In the present specification, "optional" and "optionally" mean that the subsequently described event or circumstance can or can not occur, and that the description includes situations in which the event or circumstance occurs and situations in which the event or circumstance does not occur.

[0039] In the present specification, the numerical range indicated by "numerical value A ~ numerical value B" means a range including the end point values A, B.

[0040] In the present application, "about" is used to define the numerical range and parameters of the present application as approximate values, and the relevant values in the specific examples have been presented as accurately as possible. Unless otherwise explicitly stated, it should be understood that all ranges, numbers, values, and percentages used in the present application are modified by "about". Here, "about" generally means that the actual value is within ±1% or ±0.5% of a certain value or range, depending on the error range generally allowed in the art. Further, the numerical values, numerical ranges appearing in the present application should be understood to include system errors that are unavoidable in industrial production.

[0041] As used herein, the term "and / or" encompasses all combinations of the items connected by the term. For example, "A and / or B" covers "A", "B", and "A and B". For example, "A, B, and / or C" covers "A", "B", "C", "A and B", "A and C", "B and C", and "A and B and C".

[0042] In the present application, the unit names used are international standard unit names, and if not specifically stated, the "%" used means the percentage content by weight or mass.

[0043] In the present application, "infants" means the human group under 3 years of age, which includes infants from 0 to 6 months of age, older infants from 6 to 12 months of age, and toddlers from 12 to 36 months of age.

[0044] In the present application, "children" means the human group from 3 to 6 years of age.

[0045] In the present application, "adolescents" means the human group from 7 to 18 years of age.

[0046] In the present application, "pregnant and lactating women" includes women in the gestation period and women in the lactation period.

[0047] In the present application, "middle-aged and elderly" means the human group over 41 years of age.

[0048] In the present application, "animal milk" means a liquid obtained from the mammary glands of mammals in the lactation period. The term "animal milk" should be interpreted broadly and encompasses both raw milk (i.e., a liquid obtained directly from the mammary glands) and standardized dairy products (such as, for example, skim milk or whole milk).

[0049] Unless otherwise defined, other technical and scientific terms used in the present application have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs.

[0050] < Nutritional composition >

[0051] The nutritional composition for promoting the absorption of amino acids and minerals provided by the present application comprises the essential active ingredients shown in (i)~(ii) below:

[0052] (i) α-lactalbumin;

[0053] (ii) one or both of casein phosphopeptide and 2'-fucosyllactose.

[0054] The source of the α-lactalbumin is not particularly limited in the present application, and for example, it can be derived from cow's milk, goat's milk, horse's milk, and the like. The α-lactalbumin in natural milk can be obtained by conventional separation and purification techniques, such as heat aggregation-enzymatic digestion, membrane separation-chromatography combination, selective precipitation, and the like. In addition, the α-lactalbumin described above can be obtained directly from commercially available products, in addition to being obtained by the above methods.

[0055] In the present application, the source of casein phosphopeptide (CPP) is not particularly limited. For example, it is a phosphorylated polypeptide isolated and purified from casein, particularly bovine casein (αsl, αs2, β-casein) or goat casein, by directed hydrolysis with a protease, which contains at least one phosphoserine cluster sequence Ser(P)-Ser(P)-Ser(P)-Glu-Glu, and has a molecular weight of about 2000-4000 daltons.

[0056] In the present application, the 2'-fucosyllactose (2'-FL) is a neutral trisaccharide composed of L-fucose, D-galactose and D-glucose units, with the monosaccharide L-fucose linked to the disaccharide D-lactose by an α(1→2) bond. Its molecular formula is C 18 H 32 O 15 The source of 2'-FL is not particularly limited in the present application, and typically, it can be obtained by ordinary chemical synthesis methods, microbial fermentation methods, and the like in the art. In addition, 2'-FL can also be derived from animal milk, such as cow's milk, and the like.

[0057] The present application found that, compared to α-lactalbumin alone, the combination of α-lactalbumin with casein phosphopeptide, or 2'-fucosyllactose, or casein phosphopeptide and 2'-fucosyllactose, the nutritional composition provided by the present application can more effectively promote the absorption of amino acids and minerals, i.e., there is a synergistic effect between the two or three.

[0058] In some embodiments, in the nutritional composition described in the present application, the (i) α-lactalbumin, (ii) casein phosphopeptide and / or 2'-fucosyllactose are the main active ingredients, i.e., the nutritional composition described in the present application relies mainly on the (i) α-lactalbumin, (ii) casein phosphopeptide and / or 2'-fucosyllactose contained therein to exert a specific physiological activity function, such as to help promote the absorption of amino acids and minerals. In other words, in some embodiments, the active ingredients (ingredients for exerting a specific physiological activity function, i.e., ingredients for exerting the effect of helping to promote the absorption of amino acids and minerals) of the nutritional composition consist of the following (i)~(ii) components: (i) α-lactalbumin, (ii) casein phosphopeptide and / or 2'-fucosyllactose.

[0059] In some embodiments, the nutritional composition comprises an active ingredient (an ingredient for exerting a specific physiological activity function, i.e., an ingredient for exerting an action that helps to promote absorption of amino acids and minerals) and a non-active ingredient (a substance that does not exert an action that helps to promote absorption of amino acids and minerals). Illustratively, the non-active ingredient can be other nutrients, any food-acceptable adjuvant, and / or a substance that is produced in the process of production or acquisition of the active ingredient and cannot be effectively separated from the active ingredient or does not need to be separated. In some embodiments, the nutritional composition consists of the active ingredient and the non-active ingredient.

[0060] In some embodiments, the nutritional composition further contains one or more of other kinds of whey protein other than α-lactalbumin, other kinds of bioactive peptide other than casein phosphopeptide, and other kinds of human milk oligosaccharide other than 2'-fucosyllactose.

[0061] Illustratively, the other kinds of whey protein other than α-lactalbumin include β-lactoglobulin, immunoglobulin, serum albumin, lactoferrin, etc.; the other kinds of bioactive peptide other than casein phosphopeptide include fish and shellfish-derived peptides (such as sardine, oyster hydrolyzed peptides), plant-derived peptides, etc.; and the other kinds of human milk oligosaccharide other than 2'-fucosyllactose include 3-fucosyllactose, 3'-sialyllactose, 6'-sialyllactose, lacto-N-tetraose, lacto-N-neotetraose, lacto-N-fucopentaose I, and difucosyllactose, etc., and, for these human milk oligosaccharides, the use in a manner and amount permitted by laws and regulations is possible.

[0062] In some embodiments, in the nutritional composition, the mass ratio of (i) the essential active ingredient shown to (ii) the essential active ingredient shown can be (80-250):(3-90), preferably (90-250):(3-85), for example, can be 90:4, 90:8, 90:12, 90:16, 90:20, 90:24, 90:28, 90:32, 90:36, 90:40, 90:44, 90:48, 90:52, 90:56, 90:60, 90:64, 90:68, 90:72, 90:78, 90:82, 90:86, 90:90, 120:4, 120:8, 120:12, 120:16, 120:20, 120:24, 120:28, 120:32, 120:36, 120:40, 120:44, 120:48, 120:52, 120:56, 120:60, 120:64, 120:68, 120:72, 120:78, 120:82, 120:86, 120:90, 225:4, 225:8, 225:12, 225:16, 225:20, 225:24, 225:28, 225:32, 225:36, 225:40, 225:44, 225:48, 225:52, 225:56, 225:60, 225:64, 225:68, 225:72, 225:78, 225:82, 225:86, 225:90.

[0063] In some embodiments, in the nutritional composition described in the present application, the mass ratio of the alpha-lactalbumin, the casein phosphopeptide and the 2'-fucosyllactose can be (80-250):(3-10):(40-80), preferably (90-250):(3-5):(45-80), more preferably (90-225):4:(48-78).For example, 90:4:45, 90:4:46, 90:4:47, 90:4:48, 90:4:49, 90:4:50, 90:4:51, 90:4:52, 90:4:53, 90:4:54, 90:4:55, 90:4:56, 90:4:57, 90:4:58, 90:4:59, 90:4:60, 90:4:61, 90:4:62, 90:4:63, 90:4:64, 90:4:65, 90:4:66, 90:4:67, 90:4:68, 90:4:69, 90:4:70, 90:4:71, 90:4:72, 90:4:73, 90:4:74, 90:4:75, 90:4:76, 90:4:77, 90:4:78, 90:4:79, 90:4:80, 120:4:45, 120:4:46, 120:4:47, 120:4:48, 120:4:49, 120:4:50, 120:4:51, 120:4:52, 120:4:53, 120:4:54, 120:4:55, 120:4:56, 120:4:57, 120:4:58, 120:4:59, 120:4:60, 120:4:61, 120:4:62, 120:4:63, 120:4:64, 120:4:65, 120:4:66, 120:4:67, 120:4:68, 120:4:69, 120:4:70, 120:4:71, 120:4:72, 120:4:73, 120:4:74, 120:4:75, 120:4:76, 120:4:77, 120:4:78, 120:4:79, 120:4:80, 225:4:45, 225:4:46, 225:4:47, 225:4:48, 225:4:49, 225:4:50, 225:4:51, 225:4:52, 225:4:53, 225:4:54, 225:4:55, 225:4:56, 225:4:57, 225:4:58, 225:4:59, 225:4:60, 225:4:61, 225:4:62, 225:4:63, 225:4:64, 225:4:65, 225:4:66, 225:4:67, 225:4:68, 225:4:69, 225:4:70, 225:4:71, 225:4:72, 225:4:73, 225:4:74, 225:4:75, 225:4:76, 225:4:77, 225:4:78, 225:4:79, 225:4:80, etc.

[0064] The present application does not particularly limit the form of the nutritional composition, and typically, it can be a liquid or a solid, etc. From the perspective of production, transportation, storage, and use convenience, the nutritional composition of the present application is preferably a powdered solid.

[0065] <Use of the nutritional composition>

[0066] The present application proposes that the combination of (i) α-lactalbumin, (ii) casein phosphopeptide and / or 2'-fucosyllactose in a certain ratio can help promote the absorption of amino acids and minerals, and there is a synergistic effect between α-lactalbumin and casein phosphopeptide, between α-lactalbumin and 2'-fucosyllactose, or between α-lactalbumin, casein phosphopeptide and 2'-fucosyllactose.

[0067] In some embodiments, the amino acids include essential amino acids including lysine (Lysine), tryptophan (Tryptophan), phenylalanine (Phenylalanine), methionine (Methionine), threonine (Threonine), leucine (Leucine), valine (Valine), histidine (Histidine); and non-essential amino acids including alanine (Alanine), arginine (Arginine), aspartic acid (Aspartic acid), asparagine (Asparagine), glutamic acid (Glutamic acid), glutamine (Glutamine), glycine (Glycine), proline (Proline), serine (Serine), tyrosine (Tyrosine), cysteine (Cysteine).

[0068] In some embodiments, the minerals include at least one of calcium, magnesium, iron, and zinc; preferably, the minerals include calcium, magnesium, iron, and zinc.

[0069] In some embodiments, the help in promoting the absorption of amino acids and minerals includes help in promoting the absorption of essential amino acids including lysine, tryptophan, phenylalanine, methionine, threonine, leucine, valine, histidine; non-essential amino acids including alanine, arginine, aspartic acid, asparagine, glutamic acid, glutamine, glycine, proline, serine, tyrosine, cysteine; and minerals including at least one of calcium, magnesium, iron, and zinc; preferably, the minerals include calcium, magnesium, iron, and zinc.

[0070] In some embodiments, the facilitating absorption of amino acids and minerals comprises facilitating the transmembrane transport of amino acids and minerals by intestinal cells.

[0071] In some embodiments, the facilitating absorption of amino acids and minerals comprises facilitating the expression of an amino acid transporter gene and / or the expression of an oligopeptide transporter gene. Preferably, the facilitating absorption of amino acids and minerals comprises facilitating the expression of an amino acid transporter gene and the expression of an oligopeptide transporter gene.

[0072] In some exemplary embodiments, the amino acid transporter gene comprises SLC6A14.

[0073] In some exemplary embodiments, the oligopeptide transporter gene comprises PEPT1.

[0074] The present application is not particularly limited to specific food products containing or prepared using the nutritional composition described above.

[0075] In some embodiments, the food product described in the present application is in a liquid or solid form at room temperature.

[0076] In some embodiments, the food product described in the present application is a baby food product, a child food product, an adolescent food product, a pregnant or lactating woman food product, an adult food product, or a senior food product.

[0077] In some embodiments, the food product described in the present application is a confectionery, such as a hard candy, a gummy candy, a crisp candy, a pressed candy, an aerated candy, and the like.

[0078] In some embodiments, the food product described in the present application is a beverage, such as a carbonated beverage, a tea-based beverage, a coffee-based beverage, a fruit / vegetable juice beverage, a lactic acid bacteria beverage, and the like.

[0079] In some embodiments, the food product described in the present application is a dairy product, such as a milk powder, a cheese, a yogurt, a liquid milk, and the like.

[0080] In some embodiments, the food product described in the present application is a baked product, such as a bread, a cake, a cookie, and the like.

[0081] In some embodiments, the food product described in the present application is a dietary supplement, such as a hard capsule, a soft capsule, a tablet, an oral solution, a pill, a granule, a powder, and the like.

[0082] In some embodiments, in the food product described in the present application, the mass ratio of (i) the essential active ingredient shown to (ii) the essential active ingredient shown is (80-250):(3-90), preferably (90-250):(3-85), for example, it can be 90:4, 90:8, 90:12, 90:16, 90:20, 90:24, 90:28, 90:32, 90:36, 90:40, 90:44, 90:48, 90:52, 90:56, 90:60, 90:64, 90:68, 90:72, 90:78, 90:82, 90:86, 90:90, 120:4, 120:8, 120:12, 120:16, 120:20, 120:24, 120:28, 120:32, 120:36, 120:40, 120:44, 120:48, 120:52, 120:56, 120:60, 120:64, 120:68, 120:72, 120:78, 120:82, 120:86, 120:90, 225:4, 225:8, 225:12, 225:16, 225:20, 225:24, 225:28, 225:32, 225:36, 225:40, 225:44, 225:48, 225:52, 225:56, 225:60, 225:64, 225:68, 225:72, 225:78, 225:82, 225:86, 225:90.

[0083] In some embodiments, in the food product described in the present application, the mass ratio of the alpha-lactalbumin, the casein phosphopeptide and the 2'-fucosyllactose is (80-250):(3-10):(40-80), preferably (90-250):(3-5):(45-80), more preferably (90-225):4:(48-78).For example, 90:4:45, 90:4:46, 90:4:47, 90:4:48, 90:4:49, 90:4:50, 90:4:51, 90:4:52, 90:4:53, 90:4:54, 90:4:55, 90:4:56, 90:4:57, 90:4:58, 90:4:59, 90:4:60, 90:4:61, 90:4:62, 90:4:63, 90:4:64, 90:4:65, 90:4:66, 90:4:67, 90:4:68, 90:4:69, 90:4:70, 90:4:71, 90:4:72, 90:4:73, 90:4:74, 90:4:75, 90:4:76, 90:4:77, 90:4:78, 90:4:79, 90:4:80, 120:4:45, 120:4:46, 120:4:47, 120:4:48, 120:4:49, 120:4:50, 120:4:51, 120:4:52, 120:4:53, 120:4:54, 120:4:55, 120:4:56, 120:4:57, 120:4:58, 120:4:59, 120:4:60, 120:4:61, 120:4:62, 120:4:63, 120:4:64, 120:4:65, 120:4:66, 120:4:67, 120:4:68, 120:4:69, 120:4:70, 120:4:71, 120:4:72, 120:4:73, 120:4:74, 120:4:75, 120:4:76, 120:4:77, 120:4:78, 120:4:79, 120:4:80, 225:4:45, 225:4:46, 225:4:47, 225:4:48, 225:4:49, 225:4:50, 225:4:51, 225:4:52, 225:4:53, 225:4:54, 225:4:55, 225:4:56, 225:4:57, 225:4:58, 225:4:59, 225:4:60, 225:4:61, 225:4:62, 225:4:63, 225:4:64, 225:4:65, 225:4:66, 225:4:67, 225:4:68, 225:4:69, 225:4:70, 225:4:71, 225:4:72, 225:4:73, 225:4:74, 225:4:75, 225:4:76, 225:4:77, 225:4:78, 225:4:79, 225:4:80, etc.

[0084] The present application does not particularly limit the absolute content of the α-lactalbumin, the casein phosphopeptide and the 2'-fucosyllactose in the food, and the requirements of the local food-related laws and regulations can be met.

[0085] In some embodiments, the content of the α-lactalbumin is 0.5%-4.5%, the content of the casein phosphopeptide is 0.01%-0.3%, and the content of the 2'-fucosyllactose is 0.1%-4% in the food, based on the total dry matter content of the food.

[0086] In addition to the above-described components in the nutritional composition, the food can also contain other ingredients, such as other proteins / amino acids, carbohydrates, fats, vitamins, minerals, and other common food ingredients.

[0087] In addition, according to the type of food and the final needs of the target object, in some embodiments, the food contains any one or more of the following ingredients: plant product ingredients, animal dairy product ingredients, animal meat product ingredients, functional additive ingredients, and any acceptable adjuvants.

[0088] For the plant product ingredients, examples can include fruits such as figs, pomegranates, kiwis, oranges, tangerines, pineapples, strawberries, apples, bananas, grapes, pears, cherries, blueberries, blackberries, blackcurrants, cranberries, raspberries, melons, emblics, and mulberries, or extracts thereof; fruit and vegetable materials such as onions, cucumbers, tomatoes, cauliflowers, red beetroots, spinach, kohlrabi, Brussels sprouts, garlic, basil, Oregon grass, or extracts thereof; cereals such as rice (indica rice, japonica rice, waxy rice), wheat (wheat, barley, oat, rye), corn, sorghum, millet, foxtail millet, yellow rice, buckwheat, soybeans, fava beans, peas, mung beans, adzuki beans, kidney beans, or extracts thereof; nut materials such as walnuts, pistachios, cashews, hazelnuts, almonds, apricot kernels, pine nuts, peanuts, melon seeds, chestnuts, macadamia nuts, ginkgo nuts, or extracts thereof; coffee or extracts thereof; and some medicinal and edible plant materials or extracts thereof.

[0089] For the animal dairy product ingredients, examples can include fresh milk from cows, sheep, and the like, as well as full-fat milk powder, skim milk powder, concentrated whey protein powder, desalted whey powder, whey protein powder, hydrolyzed whey protein powder, casein powder, and other processed dairy products.

[0090] For the animal meat product ingredients, examples can include meat product ingredients of pigs, cows, sheep, aquatic animals, or birds.

[0091] For the functional additive ingredients, examples include vitamin supplements (e.g., vitamin A, beta-carotene, vitamin D3, vitamin E, vitamin Kl, vitamin Bl, vitamin B2, vitamin B6, vitamin B12, vitamin C, pantothenic acid, folic acid, niacin, biotin, etc.), mineral supplements (e.g., iron, copper, manganese, zinc, cobalt, nickel, chromium, vanadium, fluorine, selenium, iodine, silicon, tin, etc.), nucleotide supplements (e.g., choline, inositol, etc.), dietary fibers (e.g., inulin, konjac powder, galactooligosaccharide, fructooligosaccharide, isomaltooligosaccharide, soybean polysaccharide, cyclodextrin, resistant dextrin, soybean fiber, etc.), functional polyunsaturated fatty acid supplements (e.g., arachidonic acid oil powder, docosahexaenoic acid oil powder, etc.), and the like.

[0092] For any acceptable excipient, examples include solvents, antioxidants, antibacterial agents, thickening agents, diluents, co-solvents, stabilizers, emulsifiers, fillers, disintegrants, lubricants, coating materials, anti-caking agents, flavoring agents, sweetening agents, food flavors, food colors, and the like.

[0093] Examples

[0094] The embodiments of the present application will be described in detail below with reference to Examples, but those skilled in the art will appreciate that the following Examples are for illustrative purposes only and should not be construed as limiting the scope of the present application. In the Examples, unless otherwise specified, the procedures were carried out under conventional conditions or under the conditions recommended by the manufacturer. Unless otherwise specified, the reagents or instruments used were conventional products that can be commercially available.

[0095] Example 1: Effect of nutritional composition on free total amino acid and mineral absorption rate

[0096] Caco-2 cells have been shown to be a good model for studying the absorption of substances. Under in vitro culture conditions, the Caco-2 cell model can be used to study the absorption mechanism of substances in the small intestine, the interaction during the absorption of nutrients, and the relationship between the chemical structure of substances and in vivo transport. Therefore, the present application evaluates the absorption rate of free amino acids and minerals after digestion of each sample by Caco-2 cells by in vitro simulated digestion of different nutritional compositions, to analyze the bioavailability of different samples.

[0097] I. Experimental method

[0098] 1. Raw materials:

[0099] Alpha-lactalbumin: Arla, Alpha-10;

[0100] Casein phosphopeptide (CPP): TATUA;

[0101] 2'-fucosyllactose (2'-FL): DSM, GlyCare TM 2'-FL 9000.

[0102] 2. Cell: Caco-2 (human colorectal adenocarcinoma cell).

[0103] 3. Preparation of milk protein mineral-containing composition

[0104] According to the protein content of the sample, adjust the total protein concentration to 10 mg / mL with deionized water to prepare 50 mL of milk protein sample, and the amount of mineral added is based on the mineral addition level in infant formula, i.e. 32.7 mg of calcium, 2.8 mg of magnesium, 0.45 mg of iron, and 0.27 mg of zinc per g of protein. The content of the nutritional composition in each experimental example is shown in Table 1.

[0105] Table 1: Content of nutritional composition in each experimental example

[0106]

[0107] 4. In vitro gastrointestinal digestion experiment

[0108] The basic scheme of this experiment uses the dynamic biomimetic digestion system provided by Xiaodong Yijian Instrument and Equipment Co., Ltd. to carry out in vitro dynamic simulation digestion scheme. This method mainly includes the following digestion solution:

[0109] Preparation method of simulated gastric fluid (SGF) electrolyte stock solution: dissolve the SGF powder in the product with a clean beaker, add 0.825 mL of MgCl2(H2O)6 solution, completely dissolve and transfer to a 1 L volumetric flask, add 3.25 mL of 6M HCI, and dilute to 1 L with distilled water, then transfer to a glass reagent bottle for storage. Preparation of digestion solution simulation solution: take 98.5 mL of SGF electrolyte stock solution, add 50 μL of CaCl2·2H2O solution, adjust the pH with 6M HCI, and adjust the dynamic in vitro digestion to 3.2. Take a portion of Pepsin + Lipase and dissolve in the above solution (when dissolving the enzyme, pay attention to minimize the loss of enzyme, otherwise it will affect the enzyme concentration of the digestion solution simulation solution, it is recommended to rinse the reagent bottle with the above solution).

[0110] Simulated Intestinal Fluid (SIF): Preparation of SIF Electrolyte Stock Solution: Dissolve SIF powder in a clean beaker, add 2.75 mL of MgCl2(H2O)6 solution, and completely dissolve. Then transfer to a 1 L volumetric flask, add 1.75 mL of 6M HCl, and dilute to 1 L with distilled water. Store in a glass reagent bottle. Preparation of simulated digestive fluid: Take 98.3 mL of SIF electrolyte stock solution, add 200 μL of CaCl2(H2O)2 solution, and adjust the pH to 6.5 with 6M HCl. Dissolve a portion of Pancreatin and Bile salt in the above solution (when dissolving the enzyme, try to minimize the loss of enzyme to avoid affecting the enzyme concentration of the simulated digestive fluid).

[0111] In the gastric digestion stage, 12 100 mL centrifuge tubes were added with 30 mL of gastric juice and incubated at 37°C for 10 min. 12 portions of 30 mL of different reconstituted compositions were incubated at 37°C for 10 min and added to the incubated digestive fluid, and incubated at 37°C on a shaking table (180 r / min). The digestion time was started, and each centrifuge tube was sampled at 60 min, 1 M NaHCO3 was added to adjust the pH to 7.0, and the reaction was stopped by placing on ice. In the simulated intestinal digestion stage, 30 mL of digestion product was mixed with 30 mL of SIF and incubated at 37°C on a shaking table. Each centrifuge tube was sampled at 120 min, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride was added to a final concentration of 4 mM, and the reaction was stopped by placing on ice. The digested product was aliquoted, sealed, and stored at -20°C for subsequent digestion product determination.

[0112] 5. In vitro Caco-2 cell absorption experiment

[0113] The recovered Caco-2 cells were inoculated in culture bottles and placed in a 37°C, 5% CO2 incubator for culture. When the Caco-2 cells in the culture bottles grew to the logarithmic phase, they were inoculated in Transwell chambers, complete culture medium was added to the top and bottom sides of the filter membrane, and the culture was placed in the incubator for culture. The cell morphology was observed daily under a microscope.

[0114] 5.1 Amino acid and mineral absorption ratio and apparent permeability coefficient determination

[0115] The Caco-2 cell monolayer model formed by culturing for 21 days was used for the bidirectional transmembrane transport experiment, and the cell culture liquids on both sides of the Transwell chamber were discarded, and the chamber was washed twice with Hanks buffer solution without calcium and magnesium and was prepared for use. The final digestion products of each group were filtered using a sterilized 0.22 μm filter membrane. 0.25 mL of the sample and 0.15 mL of Hanks buffer solution without calcium and magnesium were added to the AP side of the Caco-2 cell Transwell chamber, and 1.5 mL of Hanks buffer solution without calcium and magnesium was added to the BL side, and the chamber was placed in an incubator for 2 h, and then 0.1 mL of the BL side liquid was aspirated, the inner chamber was removed, and the cells on the polycarbonate membrane were carefully scraped off and were ultrasonically broken. The content of the total amino acids in each group of the initial AP side addition and the final BL side transfer and the cells was determined by the ninhydrin colorimetric method, the content of the calcium, magnesium, iron and zinc elements in each group of the initial AP side addition and the final BL side transfer and the cells was determined by the flame atomic absorption spectrometry, and the absorption rate of the amino acids, calcium, magnesium, iron and zinc elements and the apparent permeability (Papp) of the transport were calculated for each group, respectively, and the formulae are as follows:

[0116] Papp=(dQ / dt) / (A×C0),

[0117] dQ / dt is the transport amount of the amino acids, calcium, magnesium, iron and zinc elements per unit time (mg / s); A is the transport membrane surface area (cm 2 ); and C0 is the original concentration of the amino acids, calcium, magnesium, iron and zinc elements on the AP side (μg / mL).

[0118] The absorption rate of the amino acids, calcium, magnesium, iron and zinc elements = the content of the amino acids, calcium, magnesium, iron and zinc elements in the cells / the content of the amino acids, calcium, magnesium, iron and zinc elements initially added on the AP side × 100%.

[0119] II. Experimental results

[0120] 1. Apparent permeability coefficient and absorption rate of amino acids

[0121] The apparent permeability coefficient (Papp) is a parameter for quantifying the transmembrane transport capacity of a substance, and reflects the rate of the substance through a biological membrane (such as the intestinal epithelium) under a unit concentration gradient. The Papp value is high as determined by the Caco-2 cell in vitro model, indicating that the nutrient substance has high permeability and may have good absorption potential.

[0122] The total protein concentration of each experimental example was the same, after in vitro gastrointestinal digestion model digestion, an equal amount of digestion solution was taken to the lower chamber of the Caco-2 cell in vitro absorption model, and the transport apparent permeability coefficient and absorption rate of amino acids transported to the lower chamber were as shown in Table 2 and Table 3. The results showed that compared with Comparative Example 1, the transport apparent permeability coefficient and absorption rate of total essential amino acids and total non-essential amino acids of Experimental Example 1 were all increased (P <0.05), indicating that the addition of CPP can enhance amino acid absorption; Experimental Example 2 and Experimental Example 3 increased the content of 2’-FL based on Comparative Example 1, and the results showed that compared with Comparative Example 1, the transport apparent permeability coefficient and absorption rate of total essential amino acids and total non-essential amino acids of Experimental Example 2 and Experimental Example 3 were all improved (P <0.05), indicating that 2’-FL has a significant effect on promoting amino acid absorption; Experimental Example 4 and Experimental Example 5 further increased the content of α-lactalbumin based on Experimental Example 1, and the results showed that the transport apparent permeability coefficient and absorption rate of total essential amino acids and total non-essential amino acids were further improved (P <0.05), indicating that increasing the content of α-lactalbumin can promote amino acid absorption. Based on the comparative example, α-lactalbumin, CPP and 2’-FL were added together in Experimental Example 6 to Experimental Example 11, and the results showed that the simultaneous enrichment of α-lactalbumin, CPP and 2’-FL content can further improve the transport apparent permeability coefficient and absorption rate of total essential amino acids and total non-essential amino acids (P <0.05), indicating that the nutritional composition of co-adding α-lactalbumin, CPP and 2’-FL can promote the increase of cell amino acid absorption.

[0123] Specifically, as shown in Table 2, compared with Experimental Example 1, Experimental Example 2 and Experimental Example 6, the total essential amino acid apparent permeability coefficient of Experimental Example 6 (0.72×10 -5 ) was greater than the sum of Experimental Example 1 and Experimental Example 2 (0.12×10 -5 +0.22×10 -5 ); the total essential amino acid transport absorption rate of Experimental Example 6 (11.1) was greater than the sum of Experimental Example 1 and Experimental Example 2 (2.7+2.9). As shown in Table 3, compared with Experimental Example 3, Experimental Example 5 and Experimental Example 11, the total non-essential amino acid apparent permeability coefficient of Experimental Example 11 (0.77×10 -5 ) was greater than the sum of Experimental Example 3 and Experimental Example 5 (0.12×10 -5 +0.3×10 -5 ); the total non-essential amino acid transport absorption rate of Experimental Example 11 (17.6) was greater than the sum of Experimental Example 3 and Experimental Example 5 (2.9+7.1).

[0124] The above results show that there is a synergistic effect between the nutritional composition of α-lactalbumin, CPP, and 2'-FL, which can promote cell absorption of amino acids.

[0125] Table 2: Total essential amino acid transport apparent permeability coefficient and absorption rate

[0126]

[0127] Note: Different letters indicate significant differences between treatments (P < 0.05).

[0128] Table 3: Total non-essential amino acid transport apparent permeability coefficient and absorption rate

[0129]

[0130] Note: Different letters indicate significant differences between treatments (P < 0.05).

[0131] 2. Mineral transport apparent permeability coefficient and absorption rate

[0132] The mineral concentrations of each experimental example were the same, and after digestion by the in vitro gastrointestinal digestion model, an equal amount of the digestion solution was taken to the Caco-2 cell in vitro absorption model, and the transport apparent permeability coefficient and absorption rate of calcium, magnesium, iron, and zinc transported to the lower chamber were as shown in Tables 4 to 7. The results showed that compared with Comparative Example 1, the transport apparent permeability coefficient and absorption rate of calcium, magnesium, iron, and zinc of Experimental Example 1 were all increased (P < 0.05), indicating that the addition of CPP can enhance mineral absorption; Experimental Example 2 and Experimental Example 3 increased the content of 2'-FL based on Comparative Example 1, and the results showed that compared with Comparative Example 1, the transport apparent permeability coefficient and absorption rate of calcium, magnesium, iron, and zinc of Experimental Example 2 and Experimental Example 3 were all improved (P < 0.05), indicating that 2'-FL has a significant effect on promoting mineral absorption; Experimental Example 4 and Experimental Example 5 further increased the content of α-lactalbumin based on Experimental Example 1, and the results showed that the transport apparent permeability coefficient and absorption rate of calcium, magnesium, iron, and zinc were all further improved (P < 0.05), indicating that increasing the content of α-lactalbumin can promote mineral absorption. Based on the comparative example, Experimental Examples 6 to 11 added α-lactalbumin, CPP, and 2'-FL in combination, and the results showed that the simultaneous enrichment of α-lactalbumin, CPP, and 2'-FL content can further improve the transport apparent permeability coefficient and absorption rate of calcium, magnesium, iron, and zinc (P < 0.05), indicating that the nutritional composition of α-lactalbumin, CPP, and 2'-FL added together can promote cell mineral absorption.

[0133] Specifically, as shown in Table 4, compared with Experimental Example 1, Experimental Example 2 and Experimental Example 6, the increase in the apparent permeability coefficient of calcium relative to Comparative Example 1 was greater for Experimental Example 6 (0.58 x 10 -4 ) than the sum of Experimental Example 1 and Experimental Example 2 (0.2 x 10 -4 + 0.28 x 10 -4 ); the increase in the calcium transport absorption rate relative to Comparative Example 1 was greater for Experimental Example 6 (18.7) than the sum of Experimental Example 1 and Experimental Example 2 (7.3 + 9.9). As shown in Table 5, compared with Experimental Example 3, Experimental Example 5 and Experimental Example 11, the increase in the apparent permeability coefficient of magnesium relative to Comparative Example 1 was greater for Experimental Example 11 (2.5 x 10 -6 ) than the sum of Experimental Example 3 and Experimental Example 5 (0.7 x 10 -6 + 1 x 10 -6 ); the increase in the magnesium transport absorption rate relative to Comparative Example 1 was greater for Experimental Example 11 (14.7) than the sum of Experimental Example 3 and Experimental Example 5 (4.6 + 5.9). As shown in Table 6, compared with Experimental Example 3, Experimental Example 4 and Experimental Example 10, the increase in the apparent permeability coefficient of iron relative to Comparative Example 1 was greater for Experimental Example 10 (1.47 x 10 -4 ) than the sum of Experimental Example 3 and Experimental Example 4 (0.57 x 10 -4 + 0.57 x 10 -4 ); the increase in the iron transport absorption rate relative to Comparative Example 1 was greater for Experimental Example 10 (35.8) than the sum of Experimental Example 3 and Experimental Example 4 (11.9 + 11.2). As shown in Table 7, compared with Experimental Example 2, Experimental Example 4 and Experimental Example 7, the increase in the apparent permeability coefficient of zinc relative to Comparative Example 1 was greater for Experimental Example 7 (2.7 x 10 -6 ) than the sum of Experimental Example 2 and Experimental Example 4 (1 x 10 -6 + 1.2 x 10 -6 ); the increase in the zinc transport absorption rate relative to Comparative Example 1 was greater for Experimental Example 7 (15.8) than the sum of Experimental Example 2 and Experimental Example 4 (6.1 + 7.2).

[0134] The above results show that there is a synergistic effect between the nutritional composition of a-lactalbumin, CPP and 2'-FL, which can promote the absorption of minerals by cells.

[0135] Table 4: Calcium transport apparent permeability coefficient and absorption rate

[0136]

[0137] Note: Different letters indicate significant differences between treatments (P < 0.05).

[0138] Table 5: Magnesium transport apparent permeability coefficient and absorption rate

[0139]

[0140] Note: Different letters indicate significant difference (P < 0.05) between treatments.

[0141] Table 6: Apparent permeability coefficient and absorption of iron transport

[0142]

[0143] Note: Different letters indicate significant difference (P < 0.05) between treatments.

[0144] Table 7: Apparent permeability coefficient and absorption of zinc transport

[0145]

[0146] Example 2: Effect of nutritional composition on the gene expression of amino acid transporters and oligopeptide transporters

[0147] I. Experimental Methods

[0148] 1. Raw materials: same as Example 1.

[0149] 2. Cells: same as Example 1.

[0150] 3. Preparation of milk protein mineral containing composition: same as Example 1.

[0151] 4. In vitro gastrointestinal digestion: same as Example 1.

[0152] 5. In vitro Caco-2 cell absorption experiment: same as Example 1.

[0153] 5.1. Determination of the gene expression of amino acid transporters and oligopeptide transporters

[0154] The Caco-2 cell monolayer model formed by culturing for 21 days was used for bidirectional transmembrane transport experiments, and the cell culture solution on both sides of the Transwell chamber was discarded, and the Transwell chamber was washed twice with Hanks buffer solution without calcium and magnesium and was ready for use. The final digestion products of each group were filtered using a sterilized 0.22 μm filter membrane. 0.25 mL of the sample and 0.15 mL of Hanks buffer solution without calcium and magnesium were added to the AP side of the Caco-2 cell Transwell chamber, and 1.5 mL of Hanks buffer solution without calcium and magnesium was added to the BL side, and the Transwell chamber was placed in an incubator for 2 h, then 0.1 mL of the BL side liquid was aspirated, the inner chamber was removed, the cells on the polycarbonate membrane were carefully scraped off, and trizol lysis was added to extract total RNA. After the RNA was reversely transcribed into a cDNA library using a kit, specific primers were used for qPCR reaction, and the expression amounts of Caco-2 cell promoting amino acid transport protein (SLC6A14) and oligopeptide transport protein (PEPT1) were determined according to the calibration curve.

[0155] PEPT1 - forward primer: 5'-TGCCCAAGAGATGATGCTT-3' (SEQ ID NO: 1),

[0156] PEPT1 - reverse primer: 5'-CCAGTGCAAGTGATTTCAA-3' (SEQ ID NO: 2),

[0157] SLC6A14 - forward primer: 5'-TGGATTTATGGAGGGAACAGATT-3' (SEQ ID NO: 3),

[0158] SLC6A14 - reverse primer: 5'-ATCATACACCAGCCTAAAGCAAC-3' (SEQ ID NO: 4).

[0159] II. Experimental results

[0160] 1. Expression amounts of amino acid transport protein and oligopeptide transport protein genes

[0161] SLC6A14 and PEPT1 are two key solute transport proteins in intestinal epithelial cells, and they significantly affect the absorption efficiency of amino acids and oligopeptides through different mechanisms. SLC6A14 belongs to Na + / Cl - dependent transport protein and can transport 18 neutral and basic amino acids. PEPT1 is the main oligopeptide transport carrier in small intestinal epithelial cells and is responsible for transporting dipeptides and tripeptides.

[0162] The results of the amino acid transporter and oligopeptide transporter gene expression amounts are shown in Table 8. Compared with Comparative Example 1, the expression of SLC6A14 and PEPT1 in Experimental Example 1 with the addition of CPP was increased (P < 0.05); compared with Comparative Example 1, the expression of SLC6A14 and PEPT1 in Experimental Example 2 and Experimental Example 3 with the addition of 2’-FL was significantly increased (P < 0.05); compared with Experimental Example 1, the expression of SLC6A14 and PEPT1 in Experimental Example 4 and Experimental Example 5 with the increase of the content of alpha-lactalbumin was further increased (P < 0.05). Compared with Comparative Example 1, Experimental Examples 1-5, the results of each group of the combination of alpha-lactalbumin, CPP and 2’-FL in Experimental Examples 6-11 showed that the expression of SLC6A14 and PEPT1 was significantly increased (P < 0.05).

[0163] Specifically, as shown in Table 8, compared with Experimental Example 1, Experimental Example 3 and Experimental Example 9, the increase value of SLC6A14 gene expression amount in the Comparative Example 1 group, Experimental Example 9 (0.6) was greater than the sum of Experimental Example 1 and Experimental Example 3 (0.1+0.1). Compared with Experimental Example 2, Experimental Example 5 and Experimental Example 8, the increase value of PEPT1 gene expression amount in the Comparative Example 1 group, Experimental Example 8 (1.4) was greater than the sum of Experimental Example 2 and Experimental Example 5 (0.2+0.6).

[0164] The above results show that there is a synergistic effect between the nutritional composition of alpha-lactalbumin, CPP and 2’-FL, which can promote the expression of SLC6A14 and PEPT1 and improve the transport and absorption of amino acids and oligopeptides by cells.

[0165] Table 8: Transporter gene expression amount

[0166]

[0167] Note: Different letters indicate significant differences between treatments (P < 0.05).

Claims

1. A nutritional composition for promoting the absorption of amino acids and minerals, characterized in that, The nutritional composition contains the necessary active ingredients as shown in (i) and (ii) below: (i) α-lactalbumin; (ii) One or both of casein phosphopeptide and 2'-fucosylated lactose; In the nutritional composition, the mass ratio of the essential active ingredient shown in (i) to the essential active ingredient shown in (ii) is (80~250):(3~90).

2. The nutritional composition according to claim 1, characterized in that, Component (ii) includes casein phosphopeptide and 2'-fucosylated lactose. Furthermore, the mass ratio of the α-lactalbumin, the casein phosphopeptide, and the 2'-fucosylated lactose is (80~250):(3~10):(40~80).

3. The nutritional composition according to claim 1 or 2, characterized in that, The nutritional composition also includes one or more of the following: whey proteins other than α-lactalbumin, bovine milk protein derivatives other than casein phosphopeptides, and human milk oligosaccharides other than 2'-fucosylated lactose.

4. Use of the nutritional composition according to any one of claims 1 to 3 in the preparation of foods that help promote the absorption of amino acids and minerals.

5. The use according to claim 4, characterized in that, The amino acids include essential amino acids and / or non-essential amino acids.

6. The use according to claim 4 or 5, characterized in that, The minerals include one or more of calcium, zinc, magnesium, and iron.

7. The use according to any one of claims 4 to 6, characterized in that, The benefits of promoting amino acid and mineral absorption include promoting the expression of amino acid transporter genes and / or oligopeptide transporter genes.

8. The use according to any one of claims 4 to 7, characterized in that, The food products mentioned are candies, beverages, dairy products, or baked goods.

9. The use according to any one of claims 4 to 8, characterized in that, The food product is an oral preparation; the oral preparation includes at least one form selected from tablets, pills, granules, powders, capsules, beverages, jellies, gummies, and oral liquids.

Images